Research programme: anti-ED-B fusion proteins - Philogen/Bayer HealthCare

Drug Profile

Research programme: anti-ED-B fusion proteins - Philogen/Bayer HealthCare

Alternative Names: Immunoconjugates - Bayer Schering Pharma/Philogen

Latest Information Update: 28 Mar 2011

Price : $50

At a glance

  • Originator Philogen
  • Class Antibodies; Proteins
  • Mechanism of Action Angiogenesis inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 01 Mar 2011 Bayer Schering Pharma is now called Bayer Healthcare Pharmaceuticals
  • 24 Mar 2010 Preclinical development is ongoing
  • 23 Jan 2007 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top